Angiogénese
Os inibidores da angiogênese são compostos que interferem na formação de novos vasos sanguíneos, um processo crítico no crescimento e metástase do câncer. Ao inibir a angiogênese, esses compostos podem restringir o suprimento de sangue para os tumores, retardando ou interrompendo seu crescimento. Os inibidores da angiogênese são essenciais na pesquisa do câncer e no desenvolvimento terapêutico, fornecendo insights sobre os mecanismos de progressão tumoral e oferecendo potenciais tratamentos para o câncer e outras doenças relacionadas à angiogênese. Na CymitQuimica, oferecemos uma ampla gama de inibidores da angiogênese de alta qualidade para apoiar sua pesquisa em oncologia e biologia vascular.
Subcategorias de "Angiogénese"
- BTK(158 produtos)
- Bcr-Abl(113 produtos)
- EGFR(598 produtos)
- FAK(72 produtos)
- FLT(90 produtos)
- Receptor do Factor de Crescimento Fibroblasto (FGFR)(182 produtos)
- JAK(246 produtos)
- PDGFR(126 produtos)
- RAAS(90 produtos)
- Src(81 produtos)
- Syk(37 produtos)
- Trombina(53 produtos)
- VDA(2 produtos)
- VEGFR(250 produtos)
Exibir 6 mais subcategorias
Foram encontrados 2040 produtos de "Angiogénese"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
ALK/PI3K/AKT-IN-1
CAS:ALK/PI3K/AKT-IN-1 (Compound 45) effectively inhibits the proliferation of cancer cell lines A549, H1975, and PC9, with IC50 values of 0.44, 0.83, and 1.51 μM, respectively. This compound enhances the expression of p21 and p27, and decreases the activity of CDK2 and p-Rb, causing cell cycle arrest at the G1 phase. It suppresses the ALK/PI3K/AKT signaling pathway, promotes mitochondrial membrane potential depolarization, and induces apoptosis in A549 cells. Furthermore, ALK/PI3K/AKT-IN-1 inhibits the formation and growth of A549 cell spheres.Fórmula:C25H20FN5O2SCor e Forma:SolidPeso molecular:473.522FAK-IN-2
FAK-IN-2: potent oral FAK inhibitor, IC50 35 nM, reduces tumor growth, migration, and induces cell death.Fórmula:C28H31ClN8O3Cor e Forma:SolidPeso molecular:563.05CDD-1115
CAS:<p>CDD-1115 is a potent and selective BMPR2 inhibitor, with an IC50 of 1.8 nM and a Kiapp of 6.2 nM. It effectively suppresses gene expression mediated by bone morphogenetic proteins (BMPs). BMPs regulate cellular processes in various tissue types, such as the kidneys, skeletal muscle, heart, and reproductive organs, and can induce ectopic bone formation.</p>Fórmula:C32H30N6O3Cor e Forma:SolidPeso molecular:546.619VEGFR-2-IN-5 hydrochloride
VEGFR-2-IN-5 hydrochloride is an effective VEGFR2 inhibitor.Fórmula:C19H25ClN8Cor e Forma:SolidPeso molecular:400.91JBJ-09-063
CAS:JBJ-09-063: EGFR inhibitor, IC50s 0.147-0.396 nM for various mutants; hinders EGFR/Akt/ERK1/2 phosphorylation; targets TKI-sensitive/resistant lung cancer.Fórmula:C31H29FN4O3SCor e Forma:SolidPeso molecular:556.65FAK-IN-6
FAK-IN-6: Potent FAK inhibitor (IC50=1.415 nM), anti-cancer, for pancreatic studies.Fórmula:C25H31ClN5O6PSCor e Forma:SolidPeso molecular:596.04ALK-IN-31
CAS:ALK-IN-31 (Compound Ld-10) is an orally active ALK inhibitor with an IC50 of 1135 nM. It demonstrates excellent antiproliferative activity against lung cancer cells H2228, with an IC50 value of 1.35 μM. ALK-IN-31 induces apoptosis and arrests cell proliferation at the G0/G1 phase by affecting mitochondrial function. It exhibits antitumor effects by downregulating the expression of p-AKT and p-mTOR in the PI3K-AKT-mTOR signaling pathway downstream of ALK. This compound is applicable for research into non-small cell lung cancer (NSCLC).Fórmula:C30H33N5O2SCor e Forma:SolidPeso molecular:527.68RGB-286638
CAS:RGB-286638 inhibits multiple CDKs and GSK-3β, TAK1, Jak2, MEK1 with IC50s as low as 1-54 nM.Fórmula:C29H37Cl2N7O4Cor e Forma:SolidPeso molecular:618.55LSD1/EGFR-IN-1
CAS:<p>LSD1/EGFR-IN-1 (compound L-1) is an effective inhibitor of LSD1, EGFRT790M/L858R, and EGFRL858R/T790M/C797S, with IC50 values of 6.24, 2.06, and 5.01 μM, respectively. This compound plays a significant role in cancer research.</p>Fórmula:C21H20ClN3O4Cor e Forma:SolidPeso molecular:413.854JNJ-47117096
CAS:JNJ-47117096 is a potent and selective MELK inhibitor with an IC50 of 23 nM, and it also exhibits strong activity against Flt3 with an IC50 of 18 nM.Fórmula:C21H22N4O2Cor e Forma:SolidPeso molecular:362.425Tesevatinib tosylate
CAS:Tesevatinib tosylate (XL-647 tosylate) is an orally administered epidermal growth factor receptor (EGFR) inhibitor that can cross the blood-brain barrier. It significantly reduces cell viability with IC50 values of 11 nM and 102 nM in GBM12 and GBM6, respectively. Additionally, Tesevatinib tosylate inhibits HER2 (IC50=16.1 nM), VEGFR2 (IC50=1.5 nM), and Src (IC50=10.3 nM), demonstrating antitumor activity by inhibiting tumor proliferation.Fórmula:C31H33Cl2FN4O5SCor e Forma:SolidPeso molecular:663.59EGFR-IN-48
<p>EGFR-IN-48: potent EGFR inhibitor, oral, IC50: 0.193-66.7 nM, blocks EGFR mutants & BaF3/PC-9 cell proliferation.</p>Cor e Forma:SolidBMS-066
CAS:BMS-066 is an IKKβ/Tyk2 pseudokinase inhibitor. With IC50s of 9 nM and 72 nM, respectively.Fórmula:C19H21N7O2Pureza:98%Cor e Forma:SolidPeso molecular:379.42FGFR4-IN-10
FGFR4-IN-10 (compound 5a) is a potent, selective FGFR4 inhibitor with IC50 of 70.7 nM, sparing FGFR1-3.Fórmula:C20H19F3N6O3Cor e Forma:SolidPeso molecular:448.4TYK2 ligand 2
CAS:<p>TYK2ligand 2 is the TYK2 ligand of PROTACTYD-68. TYD-68 is a highly potent and selective CRBN-recruiting TYK2 PROTAC degrader with a DC50 value of 0.42 nM.</p>Fórmula:C24H20FN7O4Cor e Forma:SolidPeso molecular:489.458BTK-IN-15
BTK-IN-15: Oral BTK inhibitor, IC50 0.7 nM, induces cancer cell apoptosis, selective with anti-tumor effects.Fórmula:C28H24FN5O2Cor e Forma:SolidPeso molecular:481.52FGFR-IN-6
CAS:FGFR-IN-6 (Compound 5) is an FGFR inhibitor.Fórmula:C23H22N6O3Cor e Forma:SolidPeso molecular:430.46Tyrphostin 63
CAS:Tyrphostin 63 (compound 13) is an epidermal growth factor receptor (EGFR) inhibitor, with an IC50 of 375 μM and a Ki of 123 μM.Fórmula:C10H8N2OCor e Forma:SolidPeso molecular:172.183iBFAR2
CAS:<p>iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.</p>Fórmula:C19H15F3N2O2Cor e Forma:SolidPeso molecular:360.33EGFR-IN-133
CAS:EGFR-IN-133 (Compound 24) serves as an inhibitor targeting various mutations of the EGFR, including the wild type, L858R/T790M, d19/T790M, L858R/T790M/C797S, and d19/T790M/C797S with respective IC50 values of 0.1, 0.044, 0.036, 0.04, and 0.054 nM. The compound exhibits favorable pharmacokinetic properties and high oral bioavailability.Fórmula:C27H29F2N7O3Cor e Forma:SolidPeso molecular:537.56
